Bradley MC, Chillarige Y, Lee H, et al. – Researchers conducted a retrospective new-user cohort study to determine whether initiation of insulin glargine (glargine), compared with initiation of neutral protamine Hagedorn (NPH) or insulin detemir (detemir), is correlated with an increased risk of breast cancer in women with diabetes. They assessed female Medicare beneficiaries aged ≥ 65 years who initiated glargine, detemir, or NPH from September 2006 to September 2015, with follow-up through May 2017. No increased risk was observed with glargine use compared with either NPH or detemir by insulin use duration, follow-up length, or cumulative insulin dose. Compared with low-dose users, no increased risk of breast cancer was found in medium- or high-dose glargine users. Overall, in female Medicare beneficiaries, glargine use was not linked to an increased risk of breast cancer vs NPH or detemir.